Publication | Open Access
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease
206
Citations
26
References
2021
Year
In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30.).
| Year | Citations | |
|---|---|---|
1997 | 2K | |
2012 | 1.7K | |
1998 | 1.2K | |
2007 | 743 | |
1998 | 491 | |
1998 | 427 | |
2010 | 396 | |
2013 | 259 | |
2014 | 249 | |
2012 | 234 |
Page 1
Page 1